The United Kingdom, through the British High Commission in Kingston, Jamaica, recently supported a high-level Pharmaceutical Symposium to strengthen Jamaica’s pharmaceutical regulatory framework and improve access to safe, high-quality medicines.

The symposium, hosted in partnership with the Ministry of Health & Wellness (MOHW), the Jamaica Manufacturers and Exporters Association (JMEA), and the Jamaica Chamber of Commerce (JCC), brought together key stakeholders from across government, industry, and regulatory bodies to address critical areas in pharmaceutical drug dossier submission.

Held at The Jamaica Pegasus Hotel, the session focused on enhancing regulatory efficiency, improving the quality of submissions, and aligning Jamaica’s systems with international best practices.

The Symposium attracted significant interest, bringing together approximately 120 participants both in person and online. Attendees included representatives from government agencies, private‑sector organisations, pharmaceutical companies, and regulatory professionals.

With the participation of the UK High Commissioner to Jamaica and the Jamaican Minister of Health & Wellness, the event received high‑level institutional endorsement. Their presence underscored the importance of the continued UK–Jamaica collaboration in building robust regulatory systems and fostering an enabling environment for pharmaceutical innovation and trade.

Speaking on the importance of the initiative, British High Commissioner to Jamaica, Her Excellency Alicia Herbert said: “The UK is committed to working in partnership with Jamaica to build a modern and resilient pharmaceutical ecosystem, one that accelerates safe market access, fosters innovation, and strengthens the foundations of our shared prosperity.” 

The British High Commission’s partnership in the symposium formed part of a broader initiative that began 18 months prior to support Jamaica’s healthcare development priorities, including strengthening the country’s health systems and regulatory framework.   There were several roundtable discussions with key ministry officials on different streams and priorities, which included a UK-funded Caribbean Life Sciences, Healthcare, and Regulatory Trade Inward Mission to the United Kingdom in October 2025.  The mission included participants from the Pharmaceutical and Regulatory Affairs Branch, and conclusions from the visit formed an important component of the programme for the symposium.

During the visit, UK regulatory experts delivered detailed briefings on:

• Drug and medical device registration pathways in the United Kingdom
• Good Manufacturing Practice requirements and associated inspection processes
• Pharmacovigilance systems and post‑market surveillance
• Regulatory best practices applicable to Small Island Developing States (SIDS)

The mission to the UK extended beyond knowledge exchange. It contributed to strengthening technical regulatory capacity, advancing alignment with international standards, and deepening trust and professional collaboration between UK and Caribbean regulatory authorities.

These steps marked a significant milestone in Jamaica’s journey toward a modern, globally aligned pharmaceutical regulatory system, one that supports public health, economic growth, and expanded UK-Jamaica trade partnerships.

Minister of Health and Wellness, Dr Christopher Tufton, emphasised the significance of the symposium in advancing Jamaica’s regulatory framework and stated: “Today’s engagement is particularly significant as it places focus on one of the most critical components of our regulatory system, Pharmaceutical Drug Dossier Submission. The quality, completeness, and accuracy of these dossiers are fundamental to ensuring that medicines approved for the Jamaican market meet the highest standards of safety, efficacy, and quality. It is therefore essential that all stakeholders fully understand the technical requirements and expectations that guide this process.  This symposium continues that important dialogue – ensuring that our clients remain informed about current developments, while also providing a platform for the Division and its partners to better respond to the issues affecting the industry.”

Kathryn Silvera, President of the Jamaica Manufacturers and Exporters Association (JMEA), in her opening remarks, highlighted the importance of strong regulatory processes. She affirmed that:

“The preparation and submission of pharmaceutical drug dossiers is one of the most critical components of the product registration process. A well-prepared dossier not only facilitates efficient regulatory review but also plays a vital role in ensuring that safe, effective, and high-quality pharmaceutical products reach the patients who depend on them. As such, building competence in this area is not merely a technical exercise; it is an essential pillar in safeguarding public health. The complexity of pharmaceutical regulation demands a collective commitment to excellence, transparency, and continuous improvement”

The programme had several high-level local and international presenters, which included four (4) presenters from the UK.  Key thematic areas were included: bioequivalence requirements, regulatory reliance mechanisms, legal and policy considerations for drug registration, standards, quality systems and regulatory compliance and modernisation of dossier submission processes. 

Chief Technical Director of the Standards and Regulation Division, Dr Sean Moncrieffe, emphasised transparency and opening dialogue. He noted: “Standards and Regulation Division is happy to partner with the British High Commission, the Jamaica Chamber of Commerce and the Jamaica Manufacturers and Exporters Association to host this event.  A part of my thrust is to ensure there is clear, improved communication and open dialogue between the SRD and you, our industry partners.   You need to know that we recognise the challenges you are experiencing and we are making a significant effort to engage you and implement changes that will help to reduce your challenges and at the same time improve the output of the Division.”

The symposium served as a platform for knowledge exchange, policy dialogue, and practical guidance on elevating Jamaica’s drug registration and market authorisation processes.  Participants benefited from expert-led discussions designed to strengthen collaboration across Jamaica’s pharmaceutical and regulatory landscape, while supporting ongoing efforts to modernise systems and improve patient outcomes.

President of the Jamaica Chamber of Commerce, Emile Leiba, shared that he was happy for the deliberate action of the Ministry to give attention to a long-standing issue of pharmaceutical drug registration and added: “The JCC is pleased to have partnered with the JMEA, British High Commission and the Ministry of Health and Wellness in the staging of this symposium. The engagement of and communication with stakeholders has been identified as being critical to the improvement of our Pharmaceutical Registration process. I am encouraged by the support and the posture of the Honourable Minister Tufton on his commitment to accelerate the application of the Reliance methodology to improve efficiency where possible. This can only augur well for our country as we seek to enhance the access of Jamaicans to much-needed medicines in a safe and reliable way.”

The UK remains committed to working in partnership with Jamaica to support sustainable development in the health sector through capacity building, knowledge exchange, and strategic collaboration.